Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Form 8.3 - ALAPH LN

20 Mar 2025 15:30

RNS Number : 5159B
Syquant Capital
20 March 2025
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed:

SYQUANT CAPITAL

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Alliance Pharma plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

March 19, 2025

(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

NO

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

38,056,482

7.04%

 

 

(2) Derivatives (other than options):

3,426,367

0.63%

 

(3) Options and agreements to purchase/sell:

 

 

 

 

TOTAL:

41,482,849

7.67%

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

1p ordinary

Purchase

 

3,292,410

64 GBp

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

1p ordinary

 

CFD

 

increasing a long position

 

167,590

 

64 GBp

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

N/A

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

N/A

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

March 20, 2025

Contact name:

Laurent Boscherel

Telephone number:

+33 1 42 56 56 27

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETFLFILVEIIFIE
Date   Source Headline
14th Jan 20254:50 pmRNSForm 8.3 - Alliance Pharma 10.01.25
14th Jan 20253:00 pmBUSForm 8.3 - APH LN
14th Jan 20252:27 pmPRNForm 8.3 - Alliance Pharma PLC
14th Jan 20251:34 pmRNSForm 8.3 - Alliance Pharma plc
14th Jan 20251:31 pmRNSForm 8.3 - Alliance Pharma PLC
14th Jan 20251:08 pmGNWForm 8.3 - [ALLIANCE PHARMA PLC - 13 01 2025] - (CGWL)
14th Jan 202511:01 amRNSForm 8.3 - Alliance Pharma plc
14th Jan 202510:33 amRNSForm 8.5 (EPT/RI) - Alliance Pharma plc
14th Jan 20259:32 amGNWForm 8.5 (EPT/RI)-Alliance Pharma plc
14th Jan 20257:00 amRNSForm 8.3 - Alliance Pharma plc
14th Jan 20257:00 amRNSForm 8.3 - Alliance Pharma plc
13th Jan 20253:23 pmRNSForm 8.3 - Alliance Pharma plc
13th Jan 20252:21 pmRNSForm 8.3 - Alliance Pharma plc
13th Jan 20251:33 pmRNSForm 8.3 - Alliance Pharma PLC
13th Jan 202512:20 pmGNWForm 8.3 - [ALLIANCE PHARMA PLC - Opening Disclosure - 10 01 2025] - (CGAML)
13th Jan 202512:17 pmGNWForm 8.3 - [ALLIANCE PHARMA PLC - 10 01 2025] - (CGWL)
13th Jan 202511:58 amRNSForm 8.3 - Alliance Pharma Plc
13th Jan 202511:42 amRNSForm 8.3 - Alliance Pharma plc
13th Jan 202511:26 amGNWDimensional Fund Advisors Ltd. : Form 8.3 - ALLIANCE PHARMA PLC - Ordinary Shares
13th Jan 20259:08 amRNSForm 8.5 (EPT/RI) - Alliance Pharma plc
13th Jan 20259:02 amGNWForm 8.5 (EPT/RI)-Alliance Pharma plc
10th Jan 20252:24 pmPRNForm 8.3 - Alliance Pharma PLC
10th Jan 20252:23 pmRNSForm 8.3 - ALLIANCE PHARMA PLC
10th Jan 202511:59 amRNSForm 8 (OPD) - Alliance Pharma PLC
10th Jan 20259:54 amRNSForm 8.3 - Alliance Pharma PLC
10th Jan 20257:00 amRNSRecommended Acquisition of Alliance Pharma plc
30th Dec 20245:21 pmRNSBlock Listing Six Monthly Return
10th Oct 20246:11 pmRNSNotification of Major Holdings
30th Sep 20247:00 amRNSInterim Results
12th Sep 20247:00 amRNSNotification of Half Year Results
29th Jul 20244:10 pmRNSResult of AGM
29th Jul 20247:00 amRNSHalf Year Trading Update
23rd Jul 20246:22 pmRNSNotification of Major Holdings
23rd Jul 20246:18 pmRNSNotification of Major Holdings
23rd Jul 20246:17 pmRNSNotification of Major Holdings
23rd Jul 20247:00 amRNSSenior Management and Board Update
3rd Jul 202412:46 pmRNSAnnual Report and Notice of AGM
2nd Jul 202411:00 amRNSBlock Listing Six Monthly Return
1st Jul 20246:06 pmRNSTotal Voting Rights
27th Jun 20249:05 amRNSGrant of Options
21st Jun 202412:00 pmRNSNotification of Major Holdings
20th Jun 20242:49 pmRNSNotification of Major Holdings
20th Jun 20242:42 pmRNSNotification of Major Holdings
19th Jun 20247:00 amRNSPreliminary Results
12th Jun 20245:57 pmRNSNotification of Major Holdings
12th Jun 20242:56 pmRNSNotification of Major Holdings
12th Jun 20242:45 pmRNSNotification of Major Holdings
5th Jun 202412:35 pmRNSNotification of Major Holdings
30th May 202412:00 pmRNSNotification of Major Holdings
23rd May 20246:05 pmRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.